Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer

• Published in: Urology (Ridgewood, N.J.) Vol. 62; pp. 2 - 8
• Main Authors: Cannon, Glenn M, Walsh, Patrick C, Partin, Alan W, Pound, Charles R
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 29.12.2003
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Adenocarcinoma - radiotherapy; Adenocarcinoma - surgery; Algorithms; Androgen Antagonists - therapeutic use; Antineoplastic Agents, Hormonal - therapeutic use; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Humans; Kinetics; Male; Neoplasm Metastasis; Neoplasm Proteins - blood; Neoplasm Recurrence, Local; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - radiotherapy; Prostatic Neoplasms - surgery; Risk; Salvage Therapy; Time Factors
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2003.09.009

After primary treatment for clinically localized prostate cancer, biochemical recurrence is usually the first evidence of either local recurrence or metastatic progression. This poses a diagnostic dilemma for both the patient and the physician regarding future therapy. Prostate-specific antigen doubling time (PSADT) is a useful tool in this clinical setting. There have been multiple reports of the utility of PSADT in men with isolated biochemical recurrence after either radical prostatectomy or external-beam radiation therapy. Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence.